Parant François, Bost Muriel, Nohuz Erdogan, Prost Julie, Cerruto Emanuele, Moret Stephanie, Maurin Julien, Chene Gautier
Trace Element Analysis Laboratory, Biochemistry Department, CBAPS, Centre Hospitalier Lyon-Sud, Chemin du Grand-Revoyet, University Hospital of Lyon, 69495 Pierre-Bénite, France.
Department of Gynecology, Hôpital Femme Mère Enfant, HFME, 59 Boulevard Pinel, University Hospital of Lyon, 69500 Bron, France.
Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:434-438. doi: 10.1016/j.ejogrb.2020.07.044. Epub 2020 Jul 23.
Many patients with Essure® devices request the removal of these implants due to persistent adverse effects. The pathophysiology remains unknown, but a corrosion of the implants in the in-vivo environment leading to metal ion release may be suspected. The implants consist of polyester fibers, nickel-titanium alloy and other metals including chromium. The purpose of this study is to deliver the first results on the concentrations of nickel and chromium (two potential toxic metal elements) in peritoneal fluid and in the fallopian tube tissue during laparoscopic removal of Essure®.
In this prospective observational study conducted in a French academic research hospital (University hospital of Lyon), nickel and chromium concentrations were determined in the fallopian tube tissue and peritoneal liquid from symptomatic patients with Essure® by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) analysis in a PerkinElmer NexION 350.
Significant metal element concentrations were showed in the peritoneal fluid. There was also a differential concentration in the fallopian tube tissue with higher concentration close to the implant then lower at a distance from this implant. There was a correlation between the concentrations of the two metals.
The presence of nickel and chromium in the fallopian tube tissue and the peritoneal fluid raises the question of a possible relationship between the symptoms attributed to Essure® implants and the dissemination of potential toxic metals due to galvanic corrosion of the devices.
许多使用Essure®装置的患者因持续的不良反应而要求取出这些植入物。其病理生理学尚不清楚,但怀疑可能是植入物在体内环境中发生腐蚀导致金属离子释放。这些植入物由聚酯纤维、镍钛合金和包括铬在内的其他金属组成。本研究的目的是首次给出在腹腔镜取出Essure®期间,腹膜液和输卵管组织中镍和铬(两种潜在有毒金属元素)浓度的结果。
在法国一家学术研究医院(里昂大学医院)进行的这项前瞻性观察研究中,通过珀金埃尔默NexION 350型电感耦合等离子体质谱(ICP-MS)分析,测定了有症状的Essure®患者的输卵管组织和腹膜液中的镍和铬浓度。
腹膜液中显示出显著的金属元素浓度。输卵管组织中也存在差异浓度,靠近植入物处浓度较高,离植入物较远的地方浓度较低。两种金属的浓度之间存在相关性。
输卵管组织和腹膜液中存在镍和铬,这引发了一个问题,即Essure®植入物所致症状与装置电偶腐蚀导致潜在有毒金属扩散之间可能存在的关系。